Expression of 92-kDa type IV collagenase correlates with angiogenic markers and poor survival in head and neck squamous cell carcinoma.

Riedel, Frank; Götte, Karl; Schwalb, Joachim; Bergler, W.; Hörmann, K.

doi:10.3892/ijo.17.6.1099

Cited by 59 publications

(73 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results are in line with previous recent reports that show no correlation between circulating MMP-9 serum protein and the traditional clinicopathologic prognostic factors among HNSCC patients. 36,37 On the other hand, Riedel et al 38 have reported that serum concentrations of MMP-9 are significantly higher in patients with an advanced stage of HNSCC.…”

Section: Discussionmentioning

confidence: 99%

Serum matrix metalloproteinase‐9 in head and neck squamous cell carcinomais a prognostic marker

Ruokolainen

Pääkkö

Turpeenniemi‐Hujanen

2005

Intl Journal of Cancer

View full text Add to dashboard Cite

The aim of this study was to determine whether serum matrix metalloproteinase-9 (MMP-9) could predict cause-specific and relapse-free survival in patients with squamous cell carcinoma of head and neck. Furthermore, this study was designed to investigate whether there is an association between MMP-9 immunohistochemical staining and serum MMP-9 levels. Pretreatment serum levels of MMP-9 were quantitatively measured by ELISA assay in 67 patients presenting with a primary head and neck squamous cell carcinoma. The results were compared with the corresponding immunohistochemical staining results, clinical data and the patients' outcome. The follow-up time for all of the patients was at least 5 years. There was a statistically significant correlation between circulating MMP-9 and MMP-9 immunohistochemical staining in the corresponding tumors (p 5 0.028). The cause-specific and relapse-free survival rates were clearly lower among patients with high MMP-9 serum levels (> 73 ng/ml). The 5-year cause-specific survival-rate was 40% in a patient group with high serum MMP-9, and 69% for patients with a low MMP-9 level (p 5 0.027). In the same follow-up period, the cumulative relapsefree survival rate was 36% in patients presenting with a high serum MMP-9 and 66% in those with a low MMP-9 level. No correlation was found between MMP-9 serum levels and the traditional clinical or histopathologic factors. The results suggest for the first time that pretreatment serum MMP-9 level could serve as a prognostic factor in head and neck squamous cell carcinoma. ' 2005 Wiley-Liss, Inc.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum matrix metalloproteinase‐9 in head and neck squamous cell carcinomais a prognostic marker

Ruokolainen

Pääkkö

Turpeenniemi‐Hujanen

2005

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Due to lack of data, however, nine articles had to be excluded from the current metaanalysis. The remaining 5 publications with a total of 238 patients 7,9,[17][18][19] demonstrated MMP-9 expression in 150 tissue specimens. The common odds ratio is summarized in Table 2.…”

Section: Results For Mmp-9mentioning

confidence: 99%

“…cN status and pN status were considered in two publications, 7,17 whereas one publication considered only pN status, 18 and two other publications 9,19 did not provide any information about lymph node status. None of the studies mentioned compared levels of MMP-expression with cN status or pN status.…”

Section: Results For Mmp-9mentioning

confidence: 99%

See 1 more Smart Citation

Metaanalysis of the significance of matrix metalloproteinases for lymph node disease in patients with head and neck squamous cell carcinoma

Wiegand

Dünne

Müller

et al. 2005

Cancer

View full text Add to dashboard Cite

Objective: To study the reliability of the sentinel node technique (SNT) in the management of the N0 neck in patients with supraglottic laryngeal cancer. Methods: Patients presenting to our department, between 2001 and 2004, with T1–T3 supraglottic cancer and N0 neck, clinically and radiologically, were included in the study. All patients underwent sentinel lymph node detection, using the hand‐held gamma probe followed by bilateral modified radical neck dissection (MRND) and resection of the primary tumor. We compared the results of the SNT with those of the gold standard MRND for the staging of the neck. The histologic examination was performed after fixation for both the products of SNT and MRND. Results: Twenty‐nine patients were included in the study. Twenty‐one had T2, 2 had T1, and 6 had T3 tumors. Patients had transoral CO2 laser‐assisted resection of the primary tumor. All the patients underwent bilateral neck dissection immediately after the sentinel node biopsy. Of the 95 sentinel lymph nodes harvested, 22 were positive for lymph node metastasis. The mean number of sentinel node per patient was 3. Of the 58 modified neck dissections (2 neck sides/patient), there was 1 additional positive lymph node, in the prelaryngeal area, and the patient had already positive sentinel lymph nodes. The SNT allowed the identification of node metastasis in 100% of the cases with a sensitivity of 100 (48–100), specificity of 78 (64–88), negative predictive value of 100 (91–100). Conclusions: SNT is reliable in the staging of the clinically N0 neck in patients with supraglottic cancer. Laryngoscope, 2010

show abstract

“…71 Riedel et al have suggested that head and neck carcinomas negative for MMP-9 have smaller microvessel density than positive tumours. 72 The role of MMPs in angiogenesis has also been implicated in studies with knockout mice. 28,29 Disturbed angiogenesis has been noted in mice lacking MMP-2, -9 and MT1-MMP.…”

Section: Mmps and Tumour Angiogenesismentioning

confidence: 99%

Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets

Vihinen

Kähäri

2002

Intl Journal of Cancer

581

484

View full text Add to dashboard Cite

Degradation of extracellular matrix is crucial for malignant tumour growth, invasion, metastasis and angiogenesis. Matrix metalloproteinases (MMPs) are a family of zinc-dependent neutral endopeptidases collectively capable of degrading essentially all matrix components. Elevated levels of distinct MMPs can be detected in tumour tissue or serum of patients with advanced cancer and their role as prognostic indicators in cancer is studied. In addition, therapeutic intervention of tumour growth and invasion based on inhibition of MMP activity is under intensive investigation and several MMP inhibitors are in clinical trials in cancer. In this review, we discuss the current view on the feasibility of MMPs as prognostic markers and as targets for therapeutic intervention in cancer.

show abstract

Expression of 92-kDa type IV collagenase correlates with angiogenic markers and poor survival in head and neck squamous cell carcinoma.

Cited by 59 publications

References 0 publications

Serum matrix metalloproteinase‐9 in head and neck squamous cell carcinomais a prognostic marker

Serum matrix metalloproteinase‐9 in head and neck squamous cell carcinomais a prognostic marker

Metaanalysis of the significance of matrix metalloproteinases for lymph node disease in patients with head and neck squamous cell carcinoma

Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets

Contact Info

Product

Resources

About